SARM
GSK-971086
SaveAn early-stage non-steroidal SARM from GlaxoSmithKline evaluated in Phase I for safety and pharmacokinetics in healthy volunteers.
Quick verdict
Limited data beyond early Phase I. Development does not appear to have advanced further.
Evidence score
18/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase I data in healthy males demonstrated tolerability at tested doses. No efficacy data published. The compound appears to have been deprioritized within GSK's SARM portfolio.
Benefits
- Completed Phase I safety assessment
- Oral bioavailability confirmed in humans
Dosage notes
No therapeutic dosing established.
Side effects
- Unknown beyond Phase I tolerability data
Who should be cautious
Not approved for any indication. Only short-term safety data available.
What this page cannot tell you
No efficacy evidence. Phase I safety does not imply therapeutic benefit.
Leaderboard scores
- Muscle20
Write a review
Sign in to write a review.